Admission of New Shares & PDMR Dealing

LungLife AI, INC

22 March 2024

 

The following amendment has been made to the Admission of New Shares and PDMR Dealing announcement released on 22 March 2024 at 08:21 under RNS No 9540H.

Volume of shares figure for Andrew Boteler has been amended to 14,285 in the PDMR table contained in the announcement appendix.

All other details remain unchanged.

The full amended text is shown below.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.

22 March 2024

LungLife AI, Inc.

(the "Company" or "LungLife")

Admission of New Shares

and

PDMR Dealing

LungLife AI, Inc. (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces that, further to the Company announcements on 4 March 2025, 5 March 2024 and 21 March 2024, 5,172,621 new shares of common stock have been admitted to trading on AIM under the ticker symbol LLA and ISIN USU5500L1128 in connection with the Fundraising.

The Company also announces that it has been notified of transactions in the Company's Common Shares by directors in connection with the Fundraising, as detailed in the Appendix to the announcement.

The Company's total issued share capital now consists of 30,658,603 Common Shares of US$0.0001 each with one voting right per Common Share. There are no Common Shares held in treasury. The total number of voting rights in the Company is therefore 30,658,603. This number may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company.

Unless otherwise defined in this announcement, capitalised terms used in this announcement shall have the same meanings as defined in the Company's announcement of 4 March 2024.

For further information please contact:

LungLife AI, Inc.	www.lunglifeai.com
Paul Pagano, CEO	Via Walbrook PR
David Anderson, CFO
Investec Bank plc (Nominated Adviser & Joint Broker)	Tel: [phone]
Virginia Bull / Cameron MacRitchie / Lydia Zychowska
Goodbody Stockbrokers UC (Joint Broker) Tom Nicholson / Cameron Duncan / William Hall	Tel: [phone]
Walbrook PR Limited	Tel: [phone]
Paul McManus / Alice Woodings / Phillip Marriage	or [e-mail]

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

APPENDIX

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details  of  the  person  discharging  managerial  responsibilities  /  person  closely associated
a)	Name	Paul Pagano
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification/amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	LungLife AI, Inc.
b)	LEI	549300VBVDIF0Y3OVI38
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Common shares of US$0.0001 each ISIN: USU5500L1128
b)	Nature of the transaction	Participation in Fundraising
c)	Price(s) and volume(s)	Price(s) Volume(s) 35p 14,285
d)	Aggregated information -   Aggregated volume  -   Price	N/A N/A
e)	Date of the transaction	22 March 2024
f)	Place of the transaction	Outside a Trading Venue

1	Details  of  the  person  discharging  managerial  responsibilities  /  person  closely associated
a)	Name	David Anderson
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification/amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	LungLife AI, Inc.
b)	LEI	549300VBVDIF0Y3OVI38
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Common shares of US$0.0001 each ISIN: USU5500L1128
b)	Nature of the transaction	Participation in Fundraising
c)	Price(s) and volume(s)	Price(s) Volume(s) 35p 14,285
d)	Aggregated information -   Aggregated volume  -   Price	N/A N/A
e)	Date of the transaction	22 March 2024
f)	Place of the transaction	Outside a Trading Venue

1	Details  of  the  person  discharging  managerial  responsibilities  /  person  closely associated
a)	Name	Gordon Roy Davis
2	Reason for the notification
a)	Position/status	Non-Executive Chairman
b)	Initial notification/amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	LungLife AI, Inc.
b)	LEI	549300VBVDIF0Y3OVI38
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Common shares of US$0.0001 each ISIN: USU5500L1128
b)	Nature of the transaction	Participation in Fundraising
c)	Price(s) and volume(s)	Price(s) Volume(s) 35p 28,571
d)	Aggregated information -   Aggregated volume  -   Price	N/A N/A
e)	Date of the transaction	22 March 2024
f)	Place of the transaction	Outside a Trading Venue

1	Details  of  the  person  discharging  managerial  responsibilities  /  person  closely associated
a)	Name	Andrew Boteler
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification/amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	LungLife AI, Inc.
b)	LEI	549300VBVDIF0Y3OVI38
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Common shares of US$0.0001 each ISIN: USU5500L1128
b)	Nature of the transaction	Participation in Fundraising
c)	Price(s) and volume(s)	Price(s) Volume(s) 35p 14,285
d)	Aggregated information -   Aggregated volume  -   Price	N/A N/A
e)	Date of the transaction	22 March 2024
f)	Place of the transaction	Outside a Trading Venue

IMPORTANT NOTICES

THIS ANNOUNCEMENT, INCLUDING THE APPENDICES AND THE INFORMATION CONTAINED IN THEM, IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE, TRANSMISSION, FORWARDING OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA (COLLECTIVELY, THE "UNITED STATES"), AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL. FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.

The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), or with any securities regulatory authority of any State or other jurisdiction of the United States, and may not be offered, sold or transferred, directly or indirectly, in or into the United States, or to or for the account or benefit of US persons (as defined in Regulation S under the Securities Act ("Regulation S")), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of any State or any other jurisdiction of the United States.

 

END